Results 61 to 70 of about 9,912 (208)
Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4112-4120, May 2026.ABSTRACT Aims Evogliptin, a dipeptidyl peptidase‐4 inhibitor with a glucose‐dependent mechanism of action, is widely used as a monotherapy or in combination with other agents. However, observational studies in routine clinical settings remain limited.
Jun Hwa Hong +14 more
wiley +1 more source
International Journal of Nanomedicine, 2019 Chen-Hung Lee,1 Ming-Jer Hsieh,1 Shang-Hung Chang,1 Kuo-Chun Hung,1 Chao-Jan Wang,2 Ming-Yi Hsu,2 Jyuhn-Huarng Juang,3 I-Chang Hsieh,1 Ming-Shien Wen,1 Shih-Jung Liu4,5 1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial ...
Lee CH +9 more
doaj
IRS proteins and diabetic complications [PDF]
, 2016 IRS proteins are cellular adaptor molecules that mediate many of the key metabolic actions of insulin. When tyrosine is phosphorylated by the activated insulin receptor, IRS proteins recruit downstream effectors, such as phosphoinositide 3-kinase and ...
Brazil, Derek P. +2 more
core +1 more source
Advanced NanoBiomed Research, Volume 6, Issue 4, April 2026.This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari +5 more
wiley +1 more source
Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland [PDF]
, 2014 Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz) requires direct comparisons of the new drug with appropriate comparators determined by the Federal Joint Committee (G-BA).
Dippel, Franz-Werner +4 more
core +3 more sources
Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice -- study rationale and protocol of DIALOGUE [PDF]
, 2012 BACKGROUND: Patients with type 2 diabetes have 2–4 times greater risk for cardiovascular morbidity and mortality than those without, and this is even further aggravated if they also suffer from hypertension.
Anselm K Gitt +5 more
core +2 more sources
From Heterogeneity to Plasticity: Endothelial Dynamics in Lung Disease
Pulmonary Circulation, Volume 16, Issue 2, June 2026.ABSTRACT Endothelial heterogeneity and plasticity play an important role in lung development, homeostasis, and pathology. In recent years, increasing evidence has demonstrated that endothelial dysfunction contributes to the progression of various lung diseases, such as ADRS, PF, PH, and lung developmental disorders.
Van Dung Nguyen, Bisheng Zhou
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3126-3136, April 2026.Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami +16 more
wiley +1 more source
Valsartan and Amlodipine Improved Haematological and Biochemical Indices of Vildagliptin-treated Streptozotocin-induced Diabetic Rats [PDF]
Pharmaceutical and Biomedical ResearchBackground: Diabetes mellitus (DM) and hypertension often coexist in sufferers, which exacerbates the complications of DM. Also, the impacts of antihypertensive medications on the treatment outcomes of DM are not fully understood.
Israel Olapeju Bolanl +7 more
doaj
Frontiers in Pharmacology, 2019 Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel anti-hyperglycemic drugs for type 2 diabetes. It has been reported that DDP-4 inhibitor could exert pleiotropic effects on cardiovascular system.
Yuqin Ji +10 more
doaj +1 more source